Skip to content

Vaxcyte, Inc. PCVX Quick ratio

Quick ratio at other companies

Pfizer logo
PfizerPFE
1.2×0.0×
Merck & Co. logo
Merck & Co.MRK
1.1×-0.2×
Moderna logo
ModernaMRNA
2.4×-1.8×
Krystal Biotech, Inc. logo
Krystal Biotech, Inc.KRYS
9.1×-0.2×
ImmunityBio, Inc. logo
ImmunityBio, Inc.IBRX
6.4×+4.3×
Vertex Pharmaceuticals logo
Vertex PharmaceuticalsVRTX
2.6×+0.3×

Other financials

Income statement

See full
Operating income-$345.9M-91.3%
Net income-$320.6M-128%
EPS (diluted)-$2.30-121%

Balance sheet

See full
Cash & equivalents$262.3M-24.7%
Total debt$116.3M+33.5%
Total equity$3.0B-6.4%
Total assets$3.3B-0.9%

Cash flow

See full
Operating cash flow-$280.6M-68.8%
CapEx$2.1M-61.2%
Free cash flow-$282.7M-64.7%

Valuation

See full
Market cap$7.43B+72.0%
Enterprise value$7.28B+78.6%

Returns & leverage

See full
Return on equity-30.6%+37.9pp
Debt / equity0.0×
Current ratio7.5×-10.2×

Where this comes from

Calculated from Vaxcyte, Inc.’s reported figures.

Based on the most recent quarter.

The official record: Vaxcyte, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vaxcyte, Inc.'s quick ratio.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vaxcyte, Inc.'s quick ratio?
Vaxcyte, Inc. (PCVX) reported quick ratio of 7.5× in Q1 2026.
How has Vaxcyte, Inc.'s quick ratio changed year-over-year?
Vaxcyte, Inc.'s quick ratio decreased by 57.7% year-over-year, from 17.7× to 7.5×.
What is the long-term trend for Vaxcyte, Inc.'s quick ratio?
Over 5 years (2020 to 2025), Vaxcyte, Inc.'s quick ratio has grown at a -1.0% compound annual growth rate (CAGR), from 8.3× to 7.9×.
What does quick ratio mean?
Current assets excluding inventory, divided by current liabilities at the quarter end (the 'acid-test'). A stricter liquidity measure that excludes the least-liquid current asset.